Aortic and mitral valve disease in patients with end stage renal failure on long-term haemodialysis.

Straumann, E; Meyer, B; Misteli, M; Blumberg, A; Jenzer, H R

doi:10.1136/hrt.67.3.236

Cited by 147 publications

(96 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There may be additional factors that lead to use of warfarin in patients with ESRD. Compared with the general population, these patients have an increased incidence and prevalence of aortic valve calcification and mitral annular calcification, which lead to aortic and mitral stenosis, respectively (15)(16)(17)(18). Patients who develop mitral stenosis are often put on long-term anticoagulation because they have increased rates of atrial fibrillation and are at risk for stroke (19).…”

Section: Discussionmentioning

confidence: 99%

Subdural Hematomas in Chronic Dialysis Patients

Sood¹,

Sinson²,

Cohen³

2007

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

Background and Objectives: Subdural hematoma is a known complication of long-term hemodialysis. Design, Setting, Participants, and Measurements: The US Renal Data System was used to determine the occurrence rate of nontraumatic subdural hematoma in long-term dialysis patients and to evaluate time trends.Results: The occurrence rate of subdural hematoma in long-term dialysis patients is 10 times higher than that of the general population. From 1991 to 2002, the occurrence rate of subdural hematoma in hemodialysis patients doubled, whereas it did not change in peritoneal dialysis patients.Conclusions: This high occurrence rate of subdural hematoma and its recent increase may be related to increased use of anticoagulants in long-term hemodialysis patients.Clin J Am Soc Nephrol 2: 956-959, 2007.

show abstract

Section: Discussionmentioning

confidence: 99%

Subdural Hematomas in Chronic Dialysis Patients

Sood¹,

Sinson²,

Cohen³

2007

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

show abstract

“…Triglyceride levels, however, were higher in the statin group. The percentage of patients with congenitally bicuspid aortic valves, as well as those with endstage renal disease requiring dialysis, a known risk factor for disease progression, 15 was low and similar in both groups.…”

Section: Patient Demographicsmentioning

confidence: 99%

Effect of Hydroxymethylglutaryl Coenzyme A Reductase Inhibitors on the Progression of Calcific Aortic Stenosis

et al. 2001

View full text Add to dashboard Cite

Background-Recent studies have supported the hypothesis that calcific aortic stenosis is the product of an active inflammatory process, with similarities to atherosclerosis. We sought to determine whether therapy with hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) might slow the progression of aortic stenosis. Methods and Results-A retrospective study of 174 patients (mean age 68Ϯ12 years) with mild to moderate calcific aortic stenosis was conducted. Patients required normal left ventricular function, Յ2ϩ aortic regurgitation, and Ն2 echocardiograms performed at least 12 months apart. Fifty-seven patients (33%) received treatment with a statin; the remaining 117 (67%) did not. The statin group was older and had a higher prevalence of hypertension, diabetes mellitus, and coronary disease. During a mean follow-up of 21 months, patients treated with statin had a smaller increase in peak and mean gradient and a smaller decrease in aortic valve area. When annualized, the decrease in aortic valve area for the nonstatin group was 0.11Ϯ0.18 cm 2 compared with 0.06Ϯ0.16 cm 2 for those treated with a statin (Pϭ0.03). In multivariate analysis, statin usage was a significant independent predictor of a smaller decrease in valve area (Pϭ0.01) and a lesser increase in peak gradient (Pϭ0.02). Conclusions-Statin-treated patients, despite a higher risk profile for progression, had reduced aortic stenosis progression compared with those not treated with a statin. These data provide justification for a prospective randomized trial to substantiate whether statin therapy slows the progression of aortic stenosis.

show abstract

“…Natriuretic peptides seem to be very promising candidates, as there is great consistency in the literature on their ability to reflect the activity and progression, as well as to predict the prognosis of CAS. Although CaxP has only been correlated with the severity of CAS, it has been selected as high levels of calcium and phosphorus have been linked to increased calcification (10). Homocysteine is a marker associated with endothelial dysfunction, however due to the poor statistical power, the exact role of homocysteine in CAS could not be established (11,12).…”

Section: Selection Of Biomarkersmentioning

confidence: 99%